Status:
UNKNOWN
68Ga-P16-093 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Prostate Cancer
Eligibility:
MALE
18-90 years
Phase:
PHASE2
PHASE3
Brief Summary
Prostate-specific membrane antigen (PSMA)-targeted PET imaging with 68Ga-labeled compounds is able to provide superior sensitivity and specificity to detect primary prostate tumor and its metastases, ...
Detailed Description
Prostate cancer (PC) is one of the most common malignancies worldwide in men, with persistently high numbers dying from this disease. Due to low levels of glycolysis in prostate cancer cell, the uses ...
Eligibility Criteria
Inclusion
- confirmed treated or untreated prostate cancer patients;
- 68Ga-PSMA617 and 68Ga-P16-093 PET/CT within two consecutive days;
- signed written consent.
Exclusion
- known allergy against PSMA;
- any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Key Trial Info
Start Date :
October 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04796467
Start Date
October 1 2020
End Date
October 1 2022
Last Update
August 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730